Completed PHASE3 INTERVENTIONAL 2-arm NCT01570608

Lucentis KAV Study

Comparison of Ranibizumab (Lucentis) Monotherapy Versus Combination of Ranibizumab (Lucentis) With Photodynamic Therapy (Verteporfin) in Patients With Subfoveal Choroidal Neovascularisation Due to Age-Related Macular Degeneration - a Pilot Study

Sponsor: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Conditions Age Related Macular Degeneration

Interventions Ranibizumab Verteporfin

Updated 5 times since 2017 Last updated: Apr 3, 2012 Started: Mar 31, 2007 Primary completion: Aug 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Age Related Macular Degeneration and is currently completed. The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Data source: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria